Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary.
暂无分享,去创建一个
A. Caughey | G. Saade | J. Hobbins | B. Sibai | L. Platt | J. Copel | O. Grechukhina | W. Grobman | C. Pettker | N. Chescheir | J. Sonek | B. Bromley | Y. Afshar | C. Han | E. Werner | Divya Mallampati | Kypros Nicolaides | Hygrav Simhan | Kypros K. Nicolaides
[1] R. Adams,et al. The American College of Obstetricians and Gynecologists , 2018, Obstetrics & Gynecology.
[2] J. Hyett,et al. Cost‐effectiveness of first‐trimester screening with early preventative use of aspirin in women at high risk of early‐onset pre‐eclampsia , 2019, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[3] L. Nardozza,et al. Validation of Fetal Medicine Foundation algorithm for prediction of pre-eclampsia in the first trimester in an unselected Brazilian population , 2019, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[4] D. Rouse,et al. Aspirin strategies for preeclampsia prevention: a cost‐effectiveness analysis: 744 , 2019, American Journal of Obstetrics and Gynecology.
[5] J. Mitchell,et al. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system , 2018, British journal of pharmacology.
[6] M. Hod,et al. The first-trimester of pregnancy - A window of opportunity for prediction and prevention of pregnancy complications and future life. , 2018, Diabetes research and clinical practice.
[7] G. Jenkins,et al. Assessment of NICE and USPSTF guidelines for identifying women at high risk of pre-eclampsia for tailoring aspirin prophylaxis in pregnancy: An individual participant data meta-analysis. , 2018, European journal of obstetrics, gynecology, and reproductive biology.
[8] D. Wright,et al. Screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation , 2018, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[9] ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. , 2018, Obstetrics and gynecology.
[10] S. Cicero,et al. Comparison of diagnostic accuracy of early screening for pre‐eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE , 2018, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[11] D. Wright,et al. ASPRE trial: incidence of preterm pre‐eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm , 2018, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[12] D. Wright,et al. Aspirin for Evidence‐Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit , 2018, American journal of obstetrics and gynecology.
[13] D. Sahota,et al. First trimester screening for pre‐eclampsia in Chinese pregnancies: case–control study , 2018, BJOG : an international journal of obstetrics and gynaecology.
[14] Iris R. Mabry-Hernandez,et al. Screening for Preeclampsia. , 2018, American family physician.
[15] K. Nicolaides,et al. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis , 2017, American journal of obstetrics and gynecology.
[16] D. Mckenna,et al. First‐trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume , 2018, American journal of obstetrics and gynecology.
[17] V. Tsatsaris,et al. Aspirin for Prevention of Preeclampsia , 2017, Drugs.
[18] B. Sibai,et al. Short‐term costs of preeclampsia to the United States health care system , 2017, American journal of obstetrics and gynecology.
[19] J. Jani,et al. First-Trimester Combined Multimarker Prospective Study for the Detection of Pregnancies at a High Risk of Developing Preeclampsia Using the Fetal Medicine Foundation-Algorithm , 2017, Fetal Diagnosis and Therapy.
[20] Nicola Persico,et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia , 2017, The New England journal of medicine.
[21] S. Cicero,et al. Accuracy of competing‐risks model in screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation , 2017, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[22] Jillian T Henderson,et al. Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force , 2017, JAMA.
[23] Michael J Barry,et al. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement , 2017, JAMA.
[24] Tracy A Wolff,et al. Delivery Hospitalizations Involving Preeclampsia and Eclampsia, 2005–2014 , 2017 .
[25] K. Nicolaides,et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta‐analysis , 2017, American journal of obstetrics and gynecology.
[26] C. Chew‐Graham,et al. Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-Analysis , 2017, Circulation. Cardiovascular quality and outcomes.
[27] W. Fraser,et al. Recurrent pre-eclampsia and subsequent cardiovascular risk , 2016, Heart.
[28] D. Wright,et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. , 2016, American journal of obstetrics and gynecology.
[29] D. Rouse,et al. A Cost–Benefit Analysis of Low-Dose Aspirin Prophylaxis for the Prevention of Preeclampsia in the United States , 2015, Obstetrics and gynecology.
[30] D. Wright,et al. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. , 2015, American journal of obstetrics and gynecology.
[31] M. LeFevre. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. , 2014, Annals of internal medicine.
[32] L. Magder,et al. Prediction of preeclampsia utilizing the first trimester screening examination. , 2014, American journal of obstetrics and gynecology.
[33] A. Baschat,et al. First‐trimester prediction of pre‐eclampsia: external validity of algorithms in a prospectively enrolled cohort , 2014, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[34] Özge Tunçalp,et al. Global causes of maternal death: a WHO systematic analysis. , 2014, The Lancet. Global health.
[35] A. Ferro,et al. Mechanisms of aspirin resistance. , 2014, Pharmacology & therapeutics.
[36] Paul F Williams,et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy , 2013, The Australian & New Zealand journal of obstetrics & gynaecology.
[37] C. Ananth,et al. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis , 2013, BMJ.
[38] Yves Giguère,et al. Early Administration of Low-Dose Aspirin for the Prevention of Severe and Mild Preeclampsia: A Systematic Review and Meta-Analysis , 2012, American Journal of Perinatology.
[39] H. Meiri,et al. Economic assessment of screening for pre‐eclampsia , 2012, Prenatal diagnosis.
[40] E. Steegers,et al. Pre-eclampsia , 2010, The Lancet.
[41] François Audibert,et al. Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early Pregnancy: A Meta-Analysis , 2010, Obstetrics and gynecology.
[42] J. Moutquin,et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. , 2009, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.
[43] Anne B Wallis,et al. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. , 2008, American journal of hypertension.
[44] J. Dungan. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data , 2008 .
[45] A Metin Gülmezoglu,et al. WHO analysis of causes of maternal death: a systematic review , 2006, The Lancet.
[46] G. Dekker,et al. Pre-eclampsia , 2005, The Lancet.
[47] R. Dersimonian,et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. , 1999, JAMA.
[48] B. Sibai,et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. , 1998, The New England journal of medicine.
[49] B. Sibai,et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. , 1998, The New England journal of medicine.
[50] Jeffrey R. Wilson,et al. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women , 1994, The Lancet.
[51] S Kamen,et al. The task force. , 1976, Journal of hospital dental practice.